113 related articles for article (PubMed ID: 32304786)
1. HPV16 L1 diversity and its potential impact on the vaccination-induced immunity.
El Aliani A; El Abid H; Kassal Y; Khyatti M; Attaleb M; Ennaji MM; El Mzibri M
Gene; 2020 Jul; 747():144682. PubMed ID: 32304786
[TBL] [Abstract][Full Text] [Related]
2. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
Oumeslakht L; Ababou M; Badaoui B; Qmichou Z
Gene; 2021 May; 782():145533. PubMed ID: 33636291
[TBL] [Abstract][Full Text] [Related]
3. Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas.
Tsakogiannis D; Nikolaidis M; Zagouri F; Zografos E; Kottaridi C; Kyriakopoulou Z; Tzioga L; Markoulatos P; Amoutzias GD; Bletsa G
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680181
[TBL] [Abstract][Full Text] [Related]
4. Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by Vaccine or Natural Infection Induced Neutralizing Antibodies.
Godi A; Vaghadia S; Cocuzza C; Miller E; Beddows S
Microbiol Spectr; 2022 Jun; 10(3):e0077922. PubMed ID: 35475682
[TBL] [Abstract][Full Text] [Related]
5. Characterization of major capsid protein (L1) variants of Human papillomavirus type 16 by cervical neoplastic status in Indian women: Phylogenetic and functional analysis.
Mane A; Patil L; Limaye S; Nirmalkar A; Kulkarni-Kale U
J Med Virol; 2020 Aug; 92(8):1303-1308. PubMed ID: 31944308
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus type 16 pseudovirions with few point mutations in L1 major capsid protein FG loop could escape actual or future vaccination for potential use in gene therapy.
Fleury MJ; Touzé A; Coursaget P
Mol Biotechnol; 2014 May; 56(5):479-86. PubMed ID: 24639327
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the diversity of human papillomavirus 16 variants and L1 antigenic regions relevant for the prevention of human papillomavirus-related oropharyngeal cancer in Japan.
Yoshida T; Ogawa T; Nakanome A; Ohkoshi A; Ishii R; Higashi K; Ishikawa T; Katori Y; Furukawa T
Auris Nasus Larynx; 2022 Dec; 49(6):1033-1041. PubMed ID: 35491282
[TBL] [Abstract][Full Text] [Related]
8. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.
Ahmed AI; Bissett SL; Beddows S
Infect Genet Evol; 2013 Aug; 18():151-9. PubMed ID: 23722024
[TBL] [Abstract][Full Text] [Related]
9. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
[TBL] [Abstract][Full Text] [Related]
10. Genetic Diversity in the Major Capsid L1 Protein of HPV-16 and HPV-18 in the Netherlands.
King AJ; Sonsma JA; Vriend HJ; van der Sande MA; Feltkamp MC; Boot HJ; Koopmans MP;
PLoS One; 2016; 11(4):e0152782. PubMed ID: 27070907
[TBL] [Abstract][Full Text] [Related]
11. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
12. Genetic variability in the major capsid L1 protein of human papillomavirus type 16 (HPV-16) and 18 (HPV-18).
Frati E; Bianchi S; Colzani D; Zappa A; Orlando G; Tanzi E
Infect Genet Evol; 2011 Dec; 11(8):2119-24. PubMed ID: 21729769
[TBL] [Abstract][Full Text] [Related]
13. The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy.
Guan J; Bywaters SM; Brendle SA; Lee H; Ashley RE; Christensen ND; Hafenstein S
J Virol; 2015 Dec; 89(23):12108-17. PubMed ID: 26401038
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
15. [Production of human papillomavirus type 16 virus-like particles and its immunogenicity].
Wei MX; Li SW; Huang B; Shen WT; Su YZ; Zhang CH; Gu Y; Du HL; Zhang J; Xia NS
Bing Du Xue Bao; 2009 Jul; 25(4):245-50. PubMed ID: 19769155
[TBL] [Abstract][Full Text] [Related]
16. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
17. Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1.
Cho HJ; Shin HJ; Han IK; Jung WW; Kim YB; Sul D; Oh YK
Vaccine; 2007 Nov; 25(47):8049-57. PubMed ID: 17936447
[TBL] [Abstract][Full Text] [Related]
18. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
[TBL] [Abstract][Full Text] [Related]
19. Genetic variability of human papillomavirus type 66 L1 gene among women presenting for cervical cancer screening in Chile.
Balanda M; Fernández J; Vergara N; Campano C; Arata L; Martín HS; Ramírez E
Med Microbiol Immunol; 2019 Dec; 208(6):757-771. PubMed ID: 31165237
[TBL] [Abstract][Full Text] [Related]
20. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.
Baud D; Ponci F; Bobst M; De Grandi P; Nardelli-Haefliger D
J Virol; 2004 Dec; 78(23):12901-9. PubMed ID: 15542642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
